Skip to content

Progress of labour with hyoscine-n-butyl bromide: a randomized double-blind placebo-controlled study

Progress of labour with hyoscine-n-butyl bromide: a randomized double-blind placebo-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201908521430230
Enrollment
172
Registered
2019-08-05
Start date
2019-08-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Sponsors

Fagbohun
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Multiparous pregnant women aged 18-40 years, with singleton pregnancy in cephalic presentation, admitted in active phase (at cervical dilatation of 4 to 6 cm) of spontaneous labour at term (37 weeks – 41 weeks + 6 days gestation) whose rate of cervical dilatation is less than 1 cm per hour as assessed four hours into admission

Exclusion criteria

Exclusion criteria: Grand multiparity Multiple pregnancy Previous uterine scar Cervical dilation = 7 cm at admission Cervical cerclage Chronic or pregnancy induced medical conditions Presence of any contraindication to vaginal delivery Allergy to hyoscine-n-butyl bromide History suggestive of, or previous diagnoses of glaucoma, myasthenia gravis, obstructive uropathy, asthma, cardiac, liver or renal disease, seizure disorder or psychiatric illness Prolonged Prelabour rupture of the fetal membranes (rupture of fetal membrane with latency period greater than 24hrs) Congenital fetal malformations Intra uterine growth restriction (IUGR) Cephalopelvic disproportion Intrauterine fetal death (IUFD) Non consenting patient

Design outcomes

Primary

MeasureTime frame
1.To determine the effect of intravenous hyoscine-n-butyl bromide on the duration of active phase of labour (from the point of intervention)

Secondary

MeasureTime frame
1.To determine the effect of intravenous hyoscine-n-butyl bromide on the rate of cervical dilatation (from the point of intervention) ;2.To determine the incidence of the side effects of intravenous hyoscine-n-butyl bromide in the first stage of labour ;3.To determine the neonatal Apgar score at 1 and 5 minutes

Countries

Nigeria

Contacts

Public ContactBabatunde Olofinbiyi

Consultant Obstetrician and Gynaecologist

tundeolofinbiyi@gmail.com+2348035033677

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026